<DOC>
	<DOCNO>NCT00604890</DOCNO>
	<brief_summary>The purpose study determine safety tolerability pharmaceutical compound ( API 31510 ) topical cream topically apply superficial basal cell carcinoma obtain preliminary efficacy data treatment superficial basal cell carcinoma API 31510 topical cream . The study population include one hundred sixty ( 160 ) otherwise healthy male female adult one histologically confirm superficial basal cell carcinoma lesion . One target lesion area le one inch designate study treatment .</brief_summary>
	<brief_title>Dose-Ranging Clinical Trial Topical Creams Containing API 31510 Treatment Superficial Basal Cell Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Basal Cell</mesh_term>
	<criteria>Male female adult â‰¥ 18 year age Primary , histologically confirm sBCC minimum area 0.5 cm2 maximum diameter 2.0 cm target sBCC lesion suitable excision Histological diagnosis make 4 week prior screen visit Histological biopsy remove 25 % less target lesion No dermatological disease sBCC target site surround area Willing refrain use nonapproved lotion cream target site surround area treatment period . Willing refrain washing treated area least 8 hour follow application study medication Willing refrain exposure direct sunlight ultraviolet light avoid use tan parlor duration study Laboratory value test list Study Schedule page 2 within reference range define central laboratory , `` range '' test result clinically acceptable investigator . Ability follow study instruction likely complete study requirement Written inform consent obtain , include consent tissue examine stored central dermatopathologist Written consent allow photograph target sBCC lesion use part study data For female childbearing potential , negative pregnancy test screen use acceptable form birth control ( oral/implant/injectable/transdermal contraceptive , intrauterine device , condom , diaphragm , abstinence , monogamous relationship partner vasectomy ) Pregnant lactate Presence know suspected systemic cancer Histological evidence nBCC , SCC , tumor biopsy specimen Histological evidence severe squamous metaplasia , infiltrative , desomoplastic micronodular growth pattern biopsy specimen History recurrence target sBCC lesion Evidence dermatological disease confound skin condition treatment area , e.g. , SCC , actinic keratosis , rosacea , psoriasis , atopic dermatitis , eczema , xeroderma pigmentosa Concurrent disease treatment suppress immune system Chronic medical condition judgment investigator ( ) would interfere performance study would place patient undue risk Known sensitivity ingredient study medication Use tan parlor excessive prolonged exposure ultraviolet light direct sunlight course study Treatment systemic chemotherapeutic agent within 6 month prior screen visit Use systemic retinoids within 6 month prior screen period Treatment systemic immunomodulators immunosuppressant within 6 month prior screen period Use topical immunomodulators within 2 cm target BCC lesion within 4 week prior screen period Treatment follow topical agent within 4 week prior screen visit : levulanic acid , 5fluorouracil , coricosteroids , retinoids , diclofenac , hyaluronic acid , imiquimod Undergone facial resurfacing procedure , i.e. , chemical peel , laser resurfacing , dermabrasion , within 6 month prior screen visit , target sBCC lesion face Treatment liquid nitrogen , surgical excision curettage within 2 cm target sBCC lesion 4 week prior screen visit Elective surgery within 4 week prior screen visit , study , 4 week treatment period Evidence current chronic alcohol drug abuse Current enrollment investigational drug device study participation study within 4 week screen visit In investigator 's opinion , evidence unwillingness , inability follow restriction protocol complete study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Double-Blind</keyword>
	<keyword>Placebo</keyword>
	<keyword>Topical</keyword>
	<keyword>Treatment</keyword>
	<keyword>Dose-Ranging</keyword>
	<keyword>sBCC</keyword>
</DOC>